What is the debt of AC Immune this year?
AC Immune has a debt level of -75 CHF this year.
AC Immune Debt 2024
AC Immune Debt
-75 CHF
Ticker
ACIU
ISIN
CH0329023102
WKN
A2AR5F
In 2024, AC Immune's total debt was -75 CHF, a 160.41% change from the -28.8 CHF total debt recorded in the previous year.
AC Immune Aktienanalyse
What does AC Immune do?
AC Immune SA is a biopharmaceutical company specializing in the discovery and development of drugs for the treatment of neurodegenerative diseases as well as cancer. It was founded in 2003 by a group of leading researchers in the field of neurodegeneration and is based in Lausanne, Switzerland. The company has established itself as one of the leading companies in Alzheimer's research in recent years. AC Immune SA focuses on developing drugs targeting protein aggregation that occurs in Alzheimer's and other neurodegenerative diseases in the brain. It has developed an innovative platform technology that allows for the development of specific antibodies that selectively bind to certain toxic or disease-causing proteins. AC Immune has developed a variety of proprietary technologies and platforms that enable rapid and efficient identification, testing, and optimization of therapeutics. Its main products are antibodies that therapeutically target Alzheimer's, Parkinson's, TAU, and Alpha-Synuclein prions. These antibodies that target protein disease-related plaques help slow disease progression and alleviate symptoms. AC Immune has also developed and tested drugs for cancer treatment. The company operates in two main segments: research and development, as well as clinical studies. It has a strong pipeline of products in development that are in various stages of clinical trials. These products target various diseases including Alzheimer's, Parkinson's, advanced stage cancer, prion diseases, neurodegenerative sanatoria, and Down syndrome. AC Immune SA collaborates closely with various academic research institutions, biotechnology companies, pharmaceutical companies, and government agencies to bring innovative therapies to market. It has formed numerous partnerships and alliances with renowned partners in the pharmaceutical, biotech, and life science industries to accelerate the translation of promising therapeutic approaches into clinical applications. Recently, AC Immune SA announced a partnership with Genentech, a leading company in the development of biological therapies and diagnostic procedures. The two companies are working together to develop treatments for Alzheimer's and several other neurodegenerative diseases. Another example is the collaboration with Eli Lilly and Company for the use of ACI-3024 in the fight against tauopathies, including Alzheimer's disease and progressive supranuclear palsy. AC Immune SA has a strong foundation in scientific research and development, as well as in the commercialization of therapeutics. The company has a comprehensive product pipeline aimed at developing innovative therapy options for patients with neurodegenerative diseases and cancer. With its proprietary technology platform and partnerships with leading companies in the biotech and pharmaceutical industries, AC Immune SA has great potential to make significant advances in the development of therapies that improve patients' lives and enhance their quality of life. AC Immune ist eines der beliebtesten Unternehmen auf Eulerpool.com.Debt Details
Understanding AC Immune's Debt Structure
AC Immune's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.
Year-to-Year Comparison
Analyzing AC Immune's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.
Impact on Investments
Investors pay close attention to AC Immune’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.
Interpreting Debt Fluctuations
Shifts in AC Immune’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.
Frequently Asked Questions about AC Immune stock
What was the debt of AC Immune compared to the previous year?
The debt of AC Immune has increased by 160.41% compared to the previous year increased.
What are the consequences of high debt for investors in AC Immune?
High debt can pose a risk for investors of AC Immune, as it can weaken the company's financial position and hinder its ability to fulfill its obligations.
What are the consequences of low debt for investors of AC Immune?
Low debt means that AC Immune has a strong financial position and is able to fulfill its obligations without overburdening its finances.
How does an increase in debt from AC Immune affect the company?
An increase in debt of AC Immune can adversely affect the financial condition of the company and result in a higher burden on its finances.
How does a reduction of debt of AC Immune affect the company?
A reduction in debt of AC Immune can strengthen the company's financial position and improve its ability to meet its financial obligations.
What are some factors that influence the debt of AC Immune?
Some factors that can influence the debt of AC Immune include investments, acquisitions, operating costs, and revenue development.
Why are the debts of AC Immune so important for investors?
The debts of AC Immune are important for investors as they serve as an indicator of the company's financial stability. It provides investors with information on how the company fulfills its financial obligations.
What strategic measures can AC Immune take to change the debt?
To change the debt, AC Immune can take measures such as cost savings, increasing revenue, selling assets, making investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to change its debt.
How much dividend does AC Immune pay?
Over the past 12 months, AC Immune paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, AC Immune is expected to pay a dividend of 0 CHF.
What is the dividend yield of AC Immune?
The current dividend yield of AC Immune is .
When does AC Immune pay dividends?
AC Immune pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of AC Immune?
AC Immune paid dividends every year for the past 0 years.
What is the dividend of AC Immune?
For the upcoming 12 months, dividends amounting to 0 CHF are expected. This corresponds to a dividend yield of 0 %.
In which sector is AC Immune located?
AC Immune is assigned to the 'Health' sector.
Wann musste ich die Aktien von AC Immune kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of AC Immune from 12/3/2024 amounting to 0 CHF, you needed to have the stock in your portfolio before the ex-date on 12/3/2024.
When did AC Immune pay the last dividend?
The last dividend was paid out on 12/3/2024.
What was the dividend of AC Immune in the year 2023?
In the year 2023, AC Immune distributed 0 CHF as dividends.
In which currency does AC Immune pay out the dividend?
The dividends of AC Immune are distributed in CHF.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von AC Immune
Our stock analysis for AC Immune Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of AC Immune Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
